Ratio between fms-like Tyrosine Kinase 1 and Placental Growth Factor in Children with Congenital Heart Disease

Pediatric Cardiology

Volumn 36, Issue 3, 2015, Pages 591-599

  Sugimoto, Masaya ^a   Oka, Hideharu ^a   Kajihama, Aya ^a   Nakau, Kouichi ^a   Kuwata, Seiko ^b   Kurishima, Clara ^b   Azuma, Hiroshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Congenital heart disease; Hypoxia; Placental growth factor; Soluble fms like tyrosine kinase 1; Volume overload

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CHILD; CHILDHOOD DISEASE; COIL EMBOLIZATION; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; FALLOT TETRALOGY; FEMALE; FONTAN PROCEDURE; GLENN SHUNT; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMIC PARAMETERS; HUMAN; HYPOXIA; LUNG BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ANOXIA; BLOOD; ELECTROCARDIOGRAPHY; HEART DEFECTS, CONGENITAL; HEART STROKE VOLUME; HEART VENTRICLE; INFANT; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ANOXIA; BIOMARKERS; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; HEART DEFECTS, CONGENITAL; HEART VENTRICLES; HUMANS; INFANT; MALE; POSTOPERATIVE PERIOD; PREGNANCY PROTEINS; STROKE VOLUME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84925521972     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-014-1054-8     Document Type: Article

References (35)

1. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS (2011) Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 89:671–679
2. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
3. Givvimani S, Kundu S, Narayanan N, Armaghan F, Qipshidze N, Pushpakumar S, Vacek TP, Tyagi SC (2013) TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Arch Physiol Biochem 119:65–74
4. Grosse-Wortmann L, Al-Otay A, Yoo SJ (2009) Aortopulmonary collaterals after bidirectional cavopulmonary connection or Fontan completion: quantification with MRI. Circ Cardiovasc Imaging 2:219–225
5. Hertig A, Liere P (2010) New markers in preeclampsia. Clin Chim Acta 411:1591–1595
6. Hochholzer W, Reichlin T, Stelzig C, Hochholzer K, Meissner J, Breidthardt T, Reiter M, Duehsler B, Freidank H, Winkler K, Twerenbold R, Mueller C (2011) Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 32:326–335
7. Ichikawa H, Yagihara T, Kishimoto H, Isobe F, Yamamoto F, Nishigaki K, Matsuki O, Fujita T (1995) Extent of aortopulmonary collateral blood flow as a risk factor for Fontan operations. Ann Thorac Surg 59:433–437
8. James JL, Whitley GS, Cartwright JE (2010) Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 221:363–378
9. Kapur NK, Heffernan KS, Yunis AA, Nguyen TA, Aronovitz MJ, Parpos P, Wilson S, Baker CK, Esposito ML, Shah A, Kimmelstiel CD, Weintraub A, Karas RH, Mendelsohn ME (2011) Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion. Arterioscler Thromb Vasc Biol 31:443–450
10. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709
11. Ky B, French B, Ruparel K, Sweitzer NK, Fang JC, Levy WC, Sawyer DB, Cappola TP (2011) The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 58:386–394
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New Engl J Med 355:992–1005
13. Li H, Gu B, Zhang Y, Lewis DF, Wang Y (2005) Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 26:210–217
14. Llurba E, Sanchez O, Ferrer Q, Nicolaides KH, Ruiz A, Dominguez C, Sanchez-de-Toledo J, Garcia-Garcia B, Soro G, Arevalo S, Goya M, Suy A, Perez-Hoyos S, Alijotas-Reig J, Carreras E, Cabero L (2014) Maternal and foetal angiogenic imbalance in congenital heart defects. Euro Heart J 35:701–707
15. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267–9271
16. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW, Mussatto KA, Uzark K, Goldberg CS, Johnson WH Jr, Li J, Smith SE, Bellinger DC, Mahle WT (2012) Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. Circulation 126:1143–1172
17. Matsumoto T, Uemura S, Takeda Y, Matsui M, Okada S, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Onoue K, Kawata H, Kawakami R, Horii M, Saito Y (2013) An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease. Intern Med (Tokyo, Japan) 52: 1019–1027
18. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 111:649–658
19. McElhinney DB, Reddy VM, Tworetzky W, Petrossian E, Hanley FL, Moore P (2000) Incidence and implications of systemic to pulmonary collaterals after bidirectional cavopulmonary anastomosis. The Annals of thoracic surgery 69:1222–1228
20. Nakazawa M, Marks RA, Isabel-Jones J, Jarmakani JM (1976) Right and left ventricular volume characteristics in children with pulmonary stenosis and intact ventricular septum. Circulation 53:884–890
21. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Imagawa K, Nishida T, Morikawa Y, Takemoto Y, Asai O, Soeda T, Okayama S, Ishigami K, Nakatani K, Kawata H, Horii M, Nakajima T, Akai Y, Iwano M, Saito Y (2009) Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation 120:2470–2477
22. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y (2009) Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104:1478–1483
23. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P (2012) Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 59:740–746
24. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M (2010) Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 5:e13263
25. Prakash A, Rathod RH, Powell AJ, McElhinney DB, Banka P, Geva T (2012) Relation of systemic-to-pulmonary artery collateral flow in single ventricle physiology to palliative stage and clinical status. Am J Cardiol 109:1038–1045
26. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911–919
27. Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K, Hansson GK, Carmeliet P (2010) Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 86:29–36
28. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smitz J (2010) Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 43:768–770
29. Semenza GL (2014) Hypoxia-inducible factor 1 and cardiovascular disease. Ann Rev Physiol 76: 39–56
30. Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097–1105
31. Skibsted S, Jones AE, Puskarich MA, Arnold R, Sherwin R, Trzeciak S, Schuetz P, Aird WC, Shapiro NI (2013) Biomarkers of endothelial cell activation in early sepsis. Shock (Augusta, Ga) 39: 427-432
32. Sugimoto M, Masutani S, Seki M, Kajino H, Fujieda K, Senzaki H (2009) High serum levels of procollagen type III N-terminal amino peptide in patients with congenital heart disease. Heart (British Cardiac Society) 95:2023–2028
33. Sugimoto M, Ota K, Kajihama A, Nakau K, Manabe H, Kajino H (2011) Volume overload and pressure overload due to left-to-right shunt-induced myocardial injury. Evaluation using a highly sensitive cardiac Troponin-I assay in children with congenital heart disease. Circ J 75:2213–2219
34. Triedman JK, Bridges ND, Mayer JE Jr, Lock JE (1993) Prevalence and risk factors for aortopulmonary collateral vessels after Fontan and bidirectional Glenn procedures. J Am Coll Cardiol 22:207–215
35. Vikholm P, Schiller P, Hellgren L (2014) A modified Glenn shunt reduces venous congestion during acute right ventricular failure due to pulmonary banding: a randomized experimental study. Interact Cardiovasc Thoracic Surg 18:418–425